APPLAUSE-IgAN Clinical Trial

October 1, 2021

Currently there are no evidence-based disease-modifying pharmacotherapies for IgAN. The purpose of this clinical trial is to evaluate the superiority of LNP023 (a factor B inhibitor which works by damping the innate immune system) versus placebo on top of the maximally tolerated doses of an ACEi or ARB in slowing kidney disease progression and reduction in the protein in the urine.